Email this article Influence of ABCB1 gene polymorphism on rivaroxaban pharmacokinetics
- Authors: Kazakov R.E.1, Rodina T.A.1, Melnikov E.S.1, Danko A.A.1, Muslimova O.V.1, Demchenkova E.Y.1, Checha O.A.1, Mazerkina I.A.1, Belkov S.A.1, Prokofev A.B.1
-
Affiliations:
- Scientific Centre for Expert Evaluation of Medicinal Products
- Issue: Vol 26, No 6 (2020)
- Pages: 386-393
- Section: Clinical pharmacology and pharmaceuticals
- URL: https://medjrf.com/0869-2106/article/view/65032
- DOI: https://doi.org/10.17816/0869-2106-2020-26-6-386-393
- ID: 65032
Cite item
Open Access
Access granted
Abstract
This article presents the comparison of the pharmacogenetic and pharmacokinetic testing results in patients with atrial fibrillation taking rivaroxaban. The role of ABCB1 gene polymorphism in the variability of the pharmacological response was assessed, and the possibility of personalized treatment using therapeutic drug monitoring was discussed.
Full Text
About the authors
Ruslan E. Kazakov
Scientific Centre for Expert Evaluation of Medicinal Products
Author for correspondence.
Email: rustic100@rambler.ru
ORCID iD: 0000-0003-0802-4229
PhD (Biol.)
Russian Federation, 127051, MoscowTatyana A. Rodina
Scientific Centre for Expert Evaluation of Medicinal Products
Email: semina_tatiana@mail.ru
ORCID iD: 0000-0002-0528-3068
PhD (Chem.)
Russian Federation, 127051, MoscowEvgeny S. Melnikov
Scientific Centre for Expert Evaluation of Medicinal Products
Email: evgueniy.melnikov@gmail.com
ORCID iD: 0000-0002-8993-4808
PhD (Pharm.)
Russian Federation, 127051, MoscowAndrey A. Danko
Scientific Centre for Expert Evaluation of Medicinal Products
Email: andreida@mail.ru
ORCID iD: 0000-0002-2963-5312
MD, PhD
Russian Federation, 127051, MoscowOlga V. Muslimova
Scientific Centre for Expert Evaluation of Medicinal Products
Email: muslimova@expmed.ru
ORCID iD: 0000-0003-1009-9609
MD, PhD
Russian Federation, 127051, MoscowElena Yu. Demchenkova
Scientific Centre for Expert Evaluation of Medicinal Products
Email: demchenkova@expmed.ru
ORCID iD: 0000-0003-1972-4386
PhD (Pharm.)
Russian Federation, 127051, MoscowOlga A. Checha
Scientific Centre for Expert Evaluation of Medicinal Products
Email: checha@expmed.ru
ORCID iD: 0000-0002-7900-1078
PhD (Biol.)
Russian Federation, 127051, MoscowIrina A. Mazerkina
Scientific Centre for Expert Evaluation of Medicinal Products
Email: mazerkina@expmed.ru
ORCID iD: 0000-0002-3733-6822
MD, PhD
Russian Federation, 127051, MoscowSergey A. Belkov
Scientific Centre for Expert Evaluation of Medicinal Products
Email: evgenol-cinc@mail.ru
ORCID iD: 0000-0002-5587-5918
MD, PhD, DSc, Professor
Russian Federation, 127051, MoscowAlexey B. Prokofev
Scientific Centre for Expert Evaluation of Medicinal Products
Email: prokofiev@expmed.ru
ORCID iD: 0000-0001-7024-5546
MD, PhD, DSc, Professor
Russian Federation, 127051, MoscowReferences
- Patel MR for ROCKET AF Executive Steering Committee. Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF). Circulation. 2010;122 (Suppl 21):2217.
- Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005;5(4):262–270. doi: 10.1038/sj.tpj.6500313.
- Zimetbaum P. In the clinic atrial fibrillation. Ann Intern Med. 2010;153(11):ITC6. doi: 10.7326/0003-4819-153-11-201012070-01006.
- Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrialfibrillation using a novelrisk factor-based approach: the EuroHeart Survey on atrial fibrillation. Chest. 2010;137(2):263–272. doi: 10.1378/chest.09-1584.
- ACC/AHA/ESC Guidelines for the Management of Patients with Atrial Fibrillation. Eur Heart J. 2010;31:2369–2429.
- Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–2429. doi: 10.1093/eurheartj/ehq278.
- Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14(10):1385–1413. doi: 10.1093/europace/eus305.
- Rekomendatsii RKO, VNOA i ASSKh. Diagnosis and treatment of atrial fibrillation. Moscow; 2012. (In Russ).
- January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199–267. doi: 10.1161/CIR.0000000000000041.4.
- Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011;365(10):883–891. doi: 10.1056/NEJMoa1009638.
- Beyer-Westendorf J, Foerster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955–962. doi: 10.1182/blood-2014-03-563577.
- Douxfils J, Gosselin RC. Laboratory assessment of direct oral anticoagulants. Semin Thromb Hemost. 2017;43(3):277–290. doi: 10.1055/s-0036-1597296.
- Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 200;150(9):604–612. doi: 10.7326/0003-4819-150-9-200905050-00006.
- Rodina TA, Mel’nikov ES, Aksenov AA, Belkov SA, Sokolov AV, Prokof’ev AB, Ramenskaya GV. Development of an HPLC-MS/MS method for quantitative determination of rivaroxaban in human blood serum. Pharmaceutical Chemistry Journal. 2018;52(4):372–377.
Supplementary files
